EASL 2012 - Annual Meeting of European Association for the Study of the Liver
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:
HIGHLIGHTS
What you need to know
> Blogs > Hep Exclusives > Hepatitis News > Lessons


Safety Edge

Peg-IFN lambda has far fewer side effects vs. standard peg-IFN.



Partnership Potential

BMS/Gilead hep C drug combo show high cure rate potential.



GS-7977 vs. Geno 1

12-week 7977/IFN regimen looking good for many in ATOMIC study.


12-Week 7977/Riba for G1 HCV

SVR 4 rates vary, depending on IL-28B status.



Hope for Veterans

TMC435 regimen proves useful for prior treatment failures.



AASLD Highlights

News from November's Liver Meeting in S.F.


Abbott Duo Dynamo

ABT-450, ABT-333 interferon-free regimen shows potential.



News for Nulls

PROVIDE study: Victrelis boosts cure rates in prior null responders.



Official EASL

The 2012 International Liver Congress homepage: abstracts, webcasts and more.

NEWSFEED
EASL Coverage

HEP TV
Footage from the front lines
Jose Oliva, MD, an Allegheny General Hospital hepatologist and medical director of the medical center's liver transplant program, speaks with NBC Nightly News about the Hepatitis C epidemic and how it is affecting baby boomers.
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.